مقایسهٔ روشها
روشهای انتخابی خود را کنار هم مرور کنید؛ ردیفهای متفاوت برجسته شدهاند.
| ابزار کاکرین برای ارزیابی خطر سوگیری 2.0 در کارآزماییهای بالینی تصادفیشده× | چکلیست CONSORT: استانداردهای گزارشدهی کارآزماییهای بالینی تصادفی× | |
|---|---|---|
| حوزه | روششناسی پژوهش | روششناسی پژوهش |
| خانواده | Process / pipeline | Process / pipeline |
| سال پیدایش≠ | 2019 | 2010 (original 1996) |
| پدیدآور≠ | Jonathan Sterne, Julian Higgins (Cochrane Collaboration) | Schulz et al. (CONSORT Group) |
| نوع≠ | Clinician-rated / Research team assessment | Trial author reporting checklist |
| منبع بنیادین≠ | Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. DOI ↗ | Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The Lancet, 375(9721), 1657–1668. DOI ↗ |
| نامهای دیگر | RoB 2.0, RoB 2 | CONSORT, CONSORT 2010 |
| مرتبط | 4 | 4 |
| خلاصه≠ | RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias. | The CONSORT (Consolidated Standards of Reporting Trials) Statement is a 25-item evidence-based checklist and flow diagram developed to standardize reporting of parallel-group randomized controlled trials. First published in 1996 and updated in 2010 (CONSORT 2010), it is endorsed by over 600 journals including The Lancet, JAMA, and BMJ, and is mandatory or strongly recommended for RCT manuscript submission across clinical research. |
| ScholarGateمجموعهداده ↗ |
|
|